MX2015013175A - Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. - Google Patents

Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.

Info

Publication number
MX2015013175A
MX2015013175A MX2015013175A MX2015013175A MX2015013175A MX 2015013175 A MX2015013175 A MX 2015013175A MX 2015013175 A MX2015013175 A MX 2015013175A MX 2015013175 A MX2015013175 A MX 2015013175A MX 2015013175 A MX2015013175 A MX 2015013175A
Authority
MX
Mexico
Prior art keywords
methods
hyperproliferative diseases
coumarin derivatives
treating hyperproliferative
fibrosis
Prior art date
Application number
MX2015013175A
Other languages
English (en)
Inventor
Erik Schwiebert
John Streiff
John Dixon
Hongwu Gao
Joseph P Ritchie
Eric C Seales
Deborah Mai
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of MX2015013175A publication Critical patent/MX2015013175A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan compuestos derivados de cumarina y métodos para el tratamiento de enfermedades hiperproliferativas, tales como cáncer, enfermedad renal poliquistica y fibrosis de diferentes tejidos (por ejemplo, fibrosis pulmonar idiopática) Los métodos incluyen administrarle a un sujeto un compuesto tal como se describe en la presente. También se proporcionan métodos para inhibir la interacción entre dos o más proteínas chaperonas de choque térmico en una célula.
MX2015013175A 2013-03-15 2014-03-14 Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. MX2015013175A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788398P 2013-03-15 2013-03-15
PCT/US2014/027154 WO2014152278A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating hyperproliferative diseases

Publications (1)

Publication Number Publication Date
MX2015013175A true MX2015013175A (es) 2016-04-04

Family

ID=51581693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013175A MX2015013175A (es) 2013-03-15 2014-03-14 Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.

Country Status (10)

Country Link
US (1) US10369145B2 (es)
EP (1) EP2970249A4 (es)
JP (1) JP6407955B2 (es)
KR (1) KR20150132483A (es)
CN (1) CN105246887B (es)
AU (1) AU2014240003B2 (es)
CA (1) CA2903107C (es)
HK (1) HK1218537A1 (es)
MX (1) MX2015013175A (es)
WO (1) WO2014152278A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221840B2 (en) 2011-05-17 2015-12-29 Discoverybiomed Inc. Treating protein folding disorders with small molecule CFTR correctors
EP2922853A4 (en) 2012-11-20 2016-11-23 Discoverybiomed Inc SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES
WO2014081820A1 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors
WO2014152213A2 (en) * 2013-03-15 2014-09-25 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
KR20150132483A (ko) 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법
CN105541852B (zh) * 2016-01-29 2017-09-15 扬州大学 2‑（香豆素‑3‑基）‑6‑甲基吡啶并[5,4‑c]香豆素的合成方法
CN107098895B (zh) * 2016-02-19 2020-01-07 湖南大学 苯氨基噻唑甲基喹啉酮衍生物及其制备方法与应用
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS
CN109464440A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用
CN112274517A (zh) * 2020-10-30 2021-01-29 江苏大学 一种治疗套细胞淋巴瘤的药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003245935A1 (en) * 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101076332A (zh) 2004-10-13 2007-11-21 Ptc医疗公司 吡唑或***化合物及其用于制备治疗体细胞突变相关疾病的药物的用途
US9051342B2 (en) 2004-10-13 2015-06-09 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US20090012148A1 (en) 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
WO2009076665A1 (en) 2007-12-13 2009-06-18 Indiana University Research And Technology Corporation Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase
US20120100609A1 (en) * 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
ITMI20111068A1 (it) 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
KR20150132483A (ko) 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법
WO2014152213A2 (en) 2013-03-15 2014-09-25 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Also Published As

Publication number Publication date
CN105246887B (zh) 2018-05-11
CN105246887A (zh) 2016-01-13
HK1218537A1 (zh) 2017-02-24
EP2970249A2 (en) 2016-01-20
EP2970249A4 (en) 2017-03-15
KR20150132483A (ko) 2015-11-25
US10369145B2 (en) 2019-08-06
US20160038475A1 (en) 2016-02-11
WO2014152278A2 (en) 2014-09-25
JP6407955B2 (ja) 2018-10-17
AU2014240003A1 (en) 2015-09-03
CA2903107C (en) 2021-11-02
WO2014152278A3 (en) 2014-11-13
CA2903107A1 (en) 2014-09-25
AU2014240003B2 (en) 2017-12-14
JP2016513685A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
MX2015013175A (es) Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
PH12016500024A1 (en) Bromodomain inhibitor
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX343706B (es) Derivados heterocíclicos novedosos.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2015DN02573A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX349004B (es) Nuevos compuestos.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2013040227A3 (en) Therapeutic compounds
PH12015501088A1 (en) Dimeric compounds
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX369952B (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.
WO2016004404A3 (en) Gls1 inhibitors for treating disease
EA201591628A1 (ru) Дейтерированный палбоциклиб